BBI Solutions, Cardiff, UK, has launched galectin-3, a high-purity, multipurpose marker for cardiac failure, as well as a range of cancer types. In normal human hearts, the expression of galectin-3 is low. However, research has suggested that as the disease progresses, galectin-3 becomes rapidly and significantly up-regulated. Routine galectin-3 measurements in patients with heart failure could potentially be used to indicate disease progression and identify those patients at highest risk. In conjunction with clinical evaluation, galectin-3 can be used as a biomarker to aid in assessing the prognosis of patients with chronic heart failure. It can also be easily diluted to create different concentrations for use in cardiac risk assessments. BBI’s galectin-3 antigen is a biological, raw material with purity greater than 96%. It has the potential to be used as a control or positive sample in assays, to identify those patients at highest risk of heart failure. For more information, visit BBI.